Approval of proposal to increase the price and subsidy for warfarin (Marevan)
12 July 2013
PHARMAC is pleased to announce the approval of an agreement with GlaxoSmithKline NZ Limited relating to the supply of warfarin (Marevan). This was the subject of a consultation letter dated 19 June 2013.
In summary, the effect of the decision is that the price and subsidy for the Marevan will be increased from 1 August 2013.
Details of the decision
- The price and subsidy for all presentations of the Marevan brand of warfarin tablets will be amended in Section B, and listed in Part II of Section H, of the Pharmaceutical Schedule from 1 August 2013 as follows (expressed ex-manufacturer, excluding GST):
Chemical Presentation Brand Pack size Current price and subsidy Proposed price and subsidy Warfarin sodium Tab 1 mg Marevan 100 $5.69 $6.86 Warfarin sodium Tab 3 mg Marevan 100 $8.00 $9.70 Warfarin sodium Tab 5 mg Marevan 100 $9.64 $11.75
- Marevan will have protection from subsidy reduction and delisting until 31 July 2016.
We appreciate all of the feedback that we received and acknowledge the time people took to respond. All consultation responses received by 3 July 2013 were considered in their entirety in making a decision on the proposed changes. Most responses were supportive of the proposal.
One party responded with concerns that this proposal would limit PHARMAC’s future options in this market due to the period of protection from subsidy reduction and delisting. PHARMAC acknowledges this concern but considers that this is the best option available at this point of time to ensure continuity of supply.
If you have any questions about this decision, you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 7 March 2016